Jaguar Health Inc (JAGX)

$3.25 -3.44 (-51.42%)
Market Cap 2.49M
Revenue (ttm) 11.51M
Net Income (ttm) -53.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -464.21%
Debt to Equity Ratio -0.81
Volume 639,000
Avg Vol 30,583
Day's Range N/A - N/A
Shares Out 372,000.00
Stochastic %K 5%
Beta 0.02
Analysts Strong Buy
Price Target $16.00

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infe...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 371 8300
Address:
200 Pine Street, Suite 400, San Francisco, United States
rsiCeltics
rsiCeltics May. 5 at 9:10 AM
$GMEX $UK $JAGX logic
0 · Reply
YoungMoneyCashMoney
YoungMoneyCashMoney May. 5 at 8:32 AM
$JAGX $HCTI $ALZN $BBAI #~
0 · Reply
czarfast1
czarfast1 May. 5 at 6:13 AM
$JAGX 🤞
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun May. 5 at 2:17 AM
$JAGX yall need some mystesi!
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun May. 5 at 2:15 AM
$JAGX loading up tomorrow morning with 30 shares!
1 · Reply
MarketManStockWizzard
MarketManStockWizzard May. 5 at 1:28 AM
$JAGX just sayin
1 · Reply
Bunster
Bunster May. 4 at 11:59 PM
$JAGX imo a current pumper is reaching out to a former pumper pumping this pos on july 22 2024 ,when pps was 3,482 .50 a share. Its now 3.00 a share. It can be verified or nonverified if one has the time
0 · Reply
Bunster
Bunster May. 4 at 11:21 PM
$JAGX now i dont think nor do i know what is coming next
0 · Reply
YoungMoneyCashMoney
YoungMoneyCashMoney May. 4 at 11:13 PM
$JAGX $HCTI UP
0 · Reply
Offgridliving
Offgridliving May. 4 at 11:06 PM
$JAGX they fixed it so that makes sense why huge drop today . Tomorrow should be good 😊
1 · Reply
Latest News on JAGX
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

May 4, 2026, 8:30 AM EDT - 20 hours ago

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

Apr 29, 2026, 8:30 AM EDT - 5 days ago

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

Apr 27, 2026, 9:00 AM EDT - 7 days ago

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Apr 24, 2026, 8:30 AM EDT - 10 days ago

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

Apr 20, 2026, 4:15 PM EDT - 14 days ago

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Apr 13, 2026, 8:30 AM EDT - 21 days ago

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Jaguar Health Earnings Call Transcript: Q4 2025

Apr 10, 2026, 8:30 AM EDT - 24 days ago

Jaguar Health Earnings Call Transcript: Q4 2025

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Apr 9, 2026, 8:15 PM EDT - 25 days ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Apr 8, 2026, 8:30 AM EDT - 26 days ago

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Reports 2025 Financials

Apr 7, 2026, 8:30 AM EDT - 27 days ago

Jaguar Health Reports 2025 Financials

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Apr 2, 2026, 9:00 AM EDT - 4 weeks ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

Mar 18, 2026, 9:00 AM EDT - 6 weeks ago

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Mar 16, 2026, 9:00 AM EDT - 7 weeks ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Jaguar Health Transcript: Life Sciences Virtual Investor Forum

Mar 12, 2026, 2:00 PM EDT - 7 weeks ago

Jaguar Health Transcript: Life Sciences Virtual Investor Forum

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Mar 11, 2026, 9:00 AM EDT - 7 weeks ago

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Mar 9, 2026, 9:00 AM EDT - 2 months ago

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

Mar 3, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Mar 2, 2026, 9:00 AM EST - 2 months ago

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Jaguar Health Announces a Special One-time Stock Dividend

Feb 18, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Announces a Special One-time Stock Dividend

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jan 22, 2026, 9:00 AM EST - 3 months ago

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar Health Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 3:30 PM EST - 3 months ago

Jaguar Health Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jan 14, 2026, 9:00 AM EST - 3 months ago

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Jan 12, 2026, 9:00 AM EST - 4 months ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jan 6, 2026, 9:00 AM EST - 4 months ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jan 2, 2026, 9:00 AM EST - 4 months ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Dec 15, 2025, 9:00 AM EST - 5 months ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar Health Transcript: Emerging Growth Conference 88

Dec 10, 2025, 3:25 PM EST - 5 months ago

Jaguar Health Transcript: Emerging Growth Conference 88

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 10, 2025, 9:00 AM EST - 5 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Dec 8, 2025, 4:15 PM EST - 5 months ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Dec 2, 2025, 9:00 AM EST - 5 months ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

Nov 24, 2025, 9:00 AM EST - 5 months ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Nov 20, 2025, 9:00 AM EST - 5 months ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Jaguar Health Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 6 months ago

Jaguar Health Earnings Call Transcript: Q3 2025

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Nov 17, 2025, 8:00 AM EST - 6 months ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Nov 14, 2025, 9:00 AM EST - 6 months ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

Nov 13, 2025, 9:00 AM EST - 6 months ago

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Nov 6, 2025, 9:00 AM EST - 6 months ago

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 24, 2025, 4:15 PM EDT - 6 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Oct 6, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Jaguar Health Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 3:30 PM EDT - 7 months ago

Jaguar Health Transcript: Lytham Partners Fall 2025 Investor Conference

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Sep 30, 2025, 9:00 AM EDT - 7 months ago

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Jaguar Health Transcript: Emerging Growth Conference 2025

Sep 25, 2025, 2:55 PM EDT - 7 months ago

Jaguar Health Transcript: Emerging Growth Conference 2025

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Sep 25, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Sep 24, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Sep 23, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Sep 5, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Jaguar Health Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Jaguar Health Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Aug 21, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Jaguar Health Transcript: Emerging Growth Conference 85

Aug 20, 2025, 2:55 PM EDT - 9 months ago

Jaguar Health Transcript: Emerging Growth Conference 85

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Aug 19, 2025, 4:15 PM EDT - 9 months ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Aug 19, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Jaguar Health Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Jaguar Health Earnings Call Transcript: Q2 2025

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Aug 14, 2025, 8:00 AM EDT - 9 months ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Aug 12, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Jaguar Health Transcript: Emerging Growth Conference 84

Jul 17, 2025, 2:55 PM EDT - 10 months ago

Jaguar Health Transcript: Emerging Growth Conference 84

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jul 10, 2025, 8:30 AM EDT - 10 months ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Jul 8, 2025, 9:00 AM EDT - 10 months ago

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jun 30, 2025, 9:00 AM EDT - 11 months ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jun 26, 2025, 9:00 AM EDT - 11 months ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jun 25, 2025, 9:00 AM EDT - 11 months ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jun 24, 2025, 4:15 PM EDT - 11 months ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

rsiCeltics
rsiCeltics May. 5 at 9:10 AM
$GMEX $UK $JAGX logic
0 · Reply
YoungMoneyCashMoney
YoungMoneyCashMoney May. 5 at 8:32 AM
$JAGX $HCTI $ALZN $BBAI #~
0 · Reply
czarfast1
czarfast1 May. 5 at 6:13 AM
$JAGX 🤞
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun May. 5 at 2:17 AM
$JAGX yall need some mystesi!
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun May. 5 at 2:15 AM
$JAGX loading up tomorrow morning with 30 shares!
1 · Reply
MarketManStockWizzard
MarketManStockWizzard May. 5 at 1:28 AM
$JAGX just sayin
1 · Reply
Bunster
Bunster May. 4 at 11:59 PM
$JAGX imo a current pumper is reaching out to a former pumper pumping this pos on july 22 2024 ,when pps was 3,482 .50 a share. Its now 3.00 a share. It can be verified or nonverified if one has the time
0 · Reply
Bunster
Bunster May. 4 at 11:21 PM
$JAGX now i dont think nor do i know what is coming next
0 · Reply
YoungMoneyCashMoney
YoungMoneyCashMoney May. 4 at 11:13 PM
$JAGX $HCTI UP
0 · Reply
Offgridliving
Offgridliving May. 4 at 11:06 PM
$JAGX they fixed it so that makes sense why huge drop today . Tomorrow should be good 😊
1 · Reply
Bunster
Bunster May. 4 at 11:05 PM
$JAGX yes i did. 513,974 o/s now..The huge volume today signaled it
0 · Reply
focafoca99
focafoca99 May. 4 at 10:53 PM
$JAGX gets a Nasdaq listing deficiency notice after its 1-for-35 reverse split left it below the required 500,000 publicly held shares. https://www.rapidticker.com/news/jagx-sec-filing-b4d6b6
0 · Reply
andycoolbeans
andycoolbeans May. 4 at 10:51 PM
$JAGX https://www.stocktitan.net/sec-filings/JAGX/8-k-jaguar-health-inc-reports-material-event-fda572404850.html
0 · Reply
donemedirty
donemedirty May. 4 at 10:26 PM
$JAGX shit o n lisa
0 · Reply
andycoolbeans
andycoolbeans May. 4 at 9:39 PM
$JAGX lol this ticker is getting less bearish. Diabolical.
0 · Reply
andycoolbeans
andycoolbeans May. 4 at 9:14 PM
@Hannibal_Smith heard you followed This back in the day? $JAGX
0 · Reply
Kingjamesvii
Kingjamesvii May. 4 at 9:13 PM
$JAGX stock like this haveZERO business being on any exchange unless it is OTC!!!!
0 · Reply
Kingjamesvii
Kingjamesvii May. 4 at 9:12 PM
$JAGX I'm sure dman will be all over this. 😂
0 · Reply
The_Scientist
The_Scientist May. 4 at 9:09 PM
$JAGX how is this stock has 84k people following it. This is beyond any understanding or comprehension lol 🤣
3 · Reply
DLTT4489
DLTT4489 May. 4 at 9:03 PM
$JAGX is @Hannibal_Smith d!!!! Ck head still here pumping this garbage? 🤣 He blocked me 2 years ago
0 · Reply
DLTT4489
DLTT4489 May. 4 at 8:54 PM
$JAGX oh boy, Lisa got you again 🤣🤣🤣. Told you 🤪🤪🤪🤪🤪🤭🤭🤭🤭
0 · Reply